Physician profile
Ryan Mathew
NPI 1043664899
$34,965.31
in general payments reported to CMS, 2019-2025
28 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2022: $915 · 2023: $3,791 · 2024: $4,343 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $12K · Travel and Lodging: $3,347 · Education: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,161.00 |
| Food and Beverage | $11,937.79 |
| Travel and Lodging | $3,347.45 |
| Education | $483.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14,728.01 | 2022-2025 | |
| Abbvie INC. | $8,098.81 | 2022-2025 | |
| Sobi, INC | $2,670.38 | 2025 | |
| Amgen INC. | $1,656.55 | 2022-2025 | Enbrel, Otezla, Krystexxa |
| Mallinckrodt Hospital Products INC. | $1,058.32 | 2022-2025 | Acthar |
| Janssen Biotech, INC. | $992.77 | 2022-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $974.26 | 2022-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $872.98 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $614.88 | 2022-2025 | Benlysta |
| Genzyme Corporation | $403.86 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $398.42 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| E.R. Squibb & Sons, L.L.C. | $343.58 | 2023-2025 | Orencia |
| Lilly USA, LLC | $327.58 | 2022-2025 | Taltz, Zepbound, Olumiant |
| Aurinia Pharma U.S., INC. | $308.20 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.14 | 2023-2025 | Ofev |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $198.53 | 2022-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $177.00 | 2022-2024 | Strensiq |
| Janssen Scientific Affairs, LLC | $123.21 | 2024 | Tremfya |
| Kyowa Kirin, INC. | $120.90 | 2024 | |
| Mallinckrodt Enterprises LLC | $120.30 | 2019 | |
| Pfizer INC. | $117.63 | 2024-2025 | |
| Horizon Therapeutics Plc | $110.64 | 2023 | Krystexxa |
| Piramal Critical Care | $108.63 | 2025 | |
| Genentech USA, INC. | $84.59 | 2023-2025 | Actemra |
| Organon LLC | $47.97 | 2024-2025 | Hadlima |
| Janssen Pharmaceuticals, INC | $13.99 | 2025 | Tremfya |
| Boston Scientific Corporation | $13.18 | 2023 | Infinion 16 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.